Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Joseph Ladapo, MD, PhD

Description

Summary

Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.

Official Title

Financial Incentives for Smoking Treatment

Keywords

Smoking Cessation, Tobacco Use Cessation, Nicotine, Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), Financial incentives for smoking cessation, Financial incentives for use of evidence-based smoking cessation therapies

Eligibility

You can join if…

Open to people ages 18 years and up

  1. age ≥ 18 years
  2. smoked tobacco during the prior 30 days,
  3. have an active U.S. phone number and address,
  4. can provide consent in English or Spanish and
  5. are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit

You CAN'T join if...

  1. use only smokeless tobacco,
  2. are pregnant or breastfeeding,
  3. are discharged to an institution (e.g., nursing home, long-term care facility),
  4. are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study

Locations

  • David Geffen School of Medicine
    Los Angeles California 90095 United States
  • NYU Langone Health
    New York New York 10016 United States

Lead Scientist at UCLA

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT03979885
Study Type
Interventional
Participants
Expecting 1058 study participants
Last Updated